Open Access

Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation

  • Authors:
    • Yuan Ding
    • Juan Zhou
    • Shengyu Wang
    • Yue Li
    • Yanjun Mi
    • Shihua Gao
    • Yun Xu
    • Yuqiang Chen
    • Jianghua Yan
  • View Affiliations

  • Published online on: May 30, 2018     https://doi.org/10.3892/etm.2018.6234
  • Pages: 537-546
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neuropilin-1 (NRP-1) is involved in a range of physiological and pathological processes, including neuronal cell guidance, cardiovascular development, immunity, angiogenesis and the pathogenesis of cancer. Targeting of NRP‑1 is considered to be a potential cancer therapy and a number of approaches have been investigated, including the use of small interfering RNA, peptides, soluble NRP antagonists and monoclonal antibodies. The present study used a novel anti‑neuropilin‑1 monoclonal antibody (anti‑NRP‑1 mAb) to investigate its potential anti‑tumor effects on human gastric cancer cells in vitro and in vivo, as well as its underlying mechanisms of action. Using an MTT assay, it was observed that anti‑NRP‑1 mAb (<150 µg/ml) had no effects on the viability of gastric cancer cell line BGC‑823, while a Boyden chamber assay indicated that treatment with anti‑NRP‑1 mAb suppressed the migration and invasion of BGC‑823 cells. Western blot analysis also demonstrated that phosphorylation of Akt was reduced in BGC‑823 cells treated with anti‑NRP‑1 mAb. Furthermore, anti‑NRP‑1 mAb suppressed the growth of gastric cancer xenograft tumors and downregulated the expression of vascular endothelial growth factor proteins within tumors in nude mice. These data indicate the potential effects of anti‑NRP‑1 mAb on malignant tumors and suggest that inhibition of NRP‑1 function with anti‑NRP‑1 mAb may be a novel therapeutic approach in the treatment of cancer.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding Y, Zhou J, Wang S, Li Y, Mi Y, Gao S, Xu Y, Chen Y and Yan J: Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation. Exp Ther Med 16: 537-546, 2018
APA
Ding, Y., Zhou, J., Wang, S., Li, Y., Mi, Y., Gao, S. ... Yan, J. (2018). Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation. Experimental and Therapeutic Medicine, 16, 537-546. https://doi.org/10.3892/etm.2018.6234
MLA
Ding, Y., Zhou, J., Wang, S., Li, Y., Mi, Y., Gao, S., Xu, Y., Chen, Y., Yan, J."Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation". Experimental and Therapeutic Medicine 16.2 (2018): 537-546.
Chicago
Ding, Y., Zhou, J., Wang, S., Li, Y., Mi, Y., Gao, S., Xu, Y., Chen, Y., Yan, J."Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation". Experimental and Therapeutic Medicine 16, no. 2 (2018): 537-546. https://doi.org/10.3892/etm.2018.6234